This was the main finding of an Italian prospective longitudinal study, which included 72 SSc patients (68 female, mean age 56.6 years) who fulfilled the 2013 ACR/EULAR classification criteria for SSc. Patients with structural heart disease, heart failure, atrial fibrillation, or pulmonary hypertension were excluded from the study. An echocardiographic examination was performed for all patients at baseline and during their follow-up evaluation. Standard and speckle-tracking derived variables, including GLS, were acquired to assess systolic and diastolic function of the left (LV) and right ventricle (RV). Additional recorded data consisted of disease subset, antibodies pattern, cardiovascular risk factors, and involvement of other organ systems.
Common echocardiographic parameters of left and right systolic function were within normal range at baseline and did not change during follow-up. Mean GLS, however, worsened for both LV (from -19.8 ± 3.5% to -18.7 ± 3.5%; P=0.034) and RV (from -20.9 ± 6.1% to -18.7 ± 5.4%; P=0.013) during a median follow-up of 20 months. The increased GLS impairment registered in SSc patients was homogenous across endocardial, mesocardial, and epicardial layers of both ventricles, as well as myocardial segments. There was no difference in GLS impairment progression rate when patients were stratified according to disease subset or other clinical parameters. Dr Benfaremo urged that more studies are needed to assess the significance of subclinical heart involvement and its progression in patients with SSc.
Posted on
Previous Article
« Wide variation in prescription and dosing patterns for hydroxychloroquine in SLE Next Article
Anifrolumab achieves rapid and durable BICLA-response »
« Wide variation in prescription and dosing patterns for hydroxychloroquine in SLE Next Article
Anifrolumab achieves rapid and durable BICLA-response »
Table of Contents: EULAR 2020
Featured articles
COVID-19 and inflammatory rheumatic disease: some key issues
Secukinumab monotherapy as efficient as adalimumab
AxSpA real-life remission rates higher on biologics
Olokizumab significantly improves RA features and patient-reported outcomes
Rheumatoid Arthritis
New nanoparticle promising future agent in RA
Olokizumab significantly improves RA features and patient-reported outcomes
Low DAS at 4 months predicts sustained DMARD-free remission
Ankylosing Spondylitis
Reduced maintenance dose of certolizumab pegol can be used in axSpA
Worse response axSpA patients to second TNFi versus first TNFi
AxSpA real-life remission rates higher on biologics
Certolizumab pegol reduces acute anterior uveitis in axial spondyloarthritis
TNF-α inhibitors improve bone mineral density in AS patients
Psoriatic Arthritis
Ixekizumab shows sustained improvements in pain and fatigue at 3 years
Adalimumab added to methotrexate yields better results in PsA than methotrexate escalatio
Upadacitinib provides fast onset of improvement in psoriatic arthritis
Secukinumab monotherapy as efficient as adalimumab
Osteoporosis and Osteoarthritis
Higher mortality risk with tramadol versus NSAIDs for osteoarthritis patients
Hydroxychloroquine not effective in patients with hand osteoarthritis
Positive effect denosumab on fall risk
Systemic Sclerosis and Systemic Lupus Erythematosus
Anifrolumab achieves rapid and durable BICLA-response
Subclinical myocardial involvement progresses in SSc patients
Composite endpoint CRESS for primary Sjögren’s syndrome
COVID-19
COVID-19 and inflammatory rheumatic disease: some key issues
Related Articles
November 13, 2020
Osteoporosis in men often goes unnoticed, untreated

© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy